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Drug releaseAbstract Progress made on local anesthetics controlled release formulation and their ability to
induce motor and sensory block for a longer period of time brings signiﬁcant advantages in clinical
practice. The use of sustained release formulations provides analgesia for a long period of time with
one administration, thus limiting the complications that can occur with conventional analgesia.
Also, controlled release of a biologically active compound prevents overdosing, minimizing the side
effects, especially cardiotoxicity, neurotoxicity and tissue lesions. Clinical use of liposomal formu-
lation brings high impressive results in pain control and quick patient recovery. Increased patient
comfort, reducing to half the hospital length of stay, and treatment costs are able to provide a
higher level of healthcare.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.Contents
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Pain management represents one of the major therapeutical
goals in Intensive Care Unit [1,2]. Opioids represent the gold
standard in pain control [3]. However, their systemic adminis-
tration is associated with unwanted and potentially severe side
effects [4] such as respiratory depression, drowsiness and seda-
tion, nausea and vomiting, allergies and neutrophil disfunction
[1–7].
Therefore, many sustained release systems were studied
using local anesthetic agents [8], liposomal bupivacaine being
the most studied system [9]. The present paper presents differ-
ent liposomal systems used to obtain analgesia, and their
applications in Anesthesia and Intensive Care Unit.
2. Liposomal drug delivery systems
Liposomes are spherical, small dimension nanovesicles consist-
ing in a phospholipidical double layer [10,11]. Phospholipids
have a polar group and two hydrophobic groups, usually an
unsaturated fatty acid. Because in their constitution there is
also a hydrophilic part, a number of water soluble active sub-
stances can be encapsulated without the drug structure being
affected [12,13].
Currently, liposomes are of particular interest in clinical
treatment due to its important properties (Fig. 1). Among
these, the cell membrane biocompatibility and the ability to
graft different ligands on their surface are the most important
[10,14]. For this purpose, various controlled release systems
based on liposomal nanovesicles have been developed. Several
obstacles in drug release have been observed, mainly due to the
interaction of the nanovesicles with high density lipoproteins
in blood [15,16]. To minimize side reactions that lead to
decreased efﬁcacy of liposomal systems, nanovesicles were
biofunctionalized with various compounds, increasing theirFigure 1 Properties of liposomal nanovesicles.bioavailability and reducing their absorption by the reticuloen-
dothelial system [12,16].
2.1. Biofunctionalized polymeric liposomal system
Biofunctionalizing the liposomes with polyethylene glycol
(PEG) (Fig. 2) [15] prevents the interaction between the liposo-
mal nanovesicles and the mononuclear phagocytic system
[12,17], obtaining a higher pharmacokinetic response. Li
et al. [16] have evaluated the inﬂuence of polyethylene glycol
(PEG) upon the time that the nanovesicles are retained in
the blood. They evaluated LPD complex (liposome-polyca-
tion-DNA) [16] which was synthesized using cationic lipo-
some, nucleic acids and protamine [16]. Experimental results
highlight that by functionalizing liposomal vesicles with
PEG, the pharmacodynamic properties of liposomal systems
increase and their inactivation is minimized.
Ying Li and collaborators have investigated the conse-
quences of biofunctionalized controlled release systems com-
posed of liposomal bufalin and pectin [11]. Bufalin [19]
represents a chemotherapeutic agent mainly used for colon
cancer and gastric cancer [18]. Bufalin administration entails
a number of negative effects due to increased toxicity of the
active substance and low solubility in water. Thus, it has been
administrated in the liposomal form in order to reduce the
overconcentration in the body and increase the therapeutical
effect. In their study, liposomal bufalin has been functionalized
with citrus pectin (Fig. 3) – a non-toxic polymer, biodegrad-
able and biocompatible in order to increase the stability of
the liposomal complex [11]. Analyses have shown the beneﬁts
of biofunctionalization with a biocompatible polymer upon
liposomal controlled release systems [11] (Fig. 4).Figure 2 PEGylated lipid bilayer [15].
Figure 3 Liposomal bufalin functionalized with citrus pectin [11].
Figure 4 In vitro release kinetic proﬁles of bufalin from
liposomal bufalin (BFL), liposomal bufalin functionalized with
pectin citrus (CPL) compared to freely soluble bufalin [11].
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3.1. Chemical structure
Bupivacaine is a synthesis derivate, with chemical conﬁgura-
tion similar to the ﬁrst local anesthetic ever discovered –
cocaine [20–22]. For a local anesthetic agent to be useful, it
must have some characteristics: increased potency, sufﬁcient
duration of action, low systemic toxicity, low local toxicity,
short onset time, high solubility in water, easily sterilizing
[20,23,24]. The chemical structure of bupivacaine (see Fig. 5),
highlights different subunits: an aromatic group, an intermedi-
ate chain which includes an amide link and an amine group.
The liposolubility is due to the aromatic ring, allowing the
compound to cross the axonal membrane, essential step in
anesthetic action.Figure 5 Bupivacaine – chemical structure.Anesthetic liposolubility generates its intrinsic potency and
the onset time. Hydrolysis takes place in the amide bond, the
degradation is mainly in the liver and the degradation com-
pounds rarely induce allergic reactions [20,25,26]. An increase
in molecular volume increases the anesthetic potency to a cer-
tain level when it starts to decline. Finally, we can say that the
chemical structure inﬂuences anesthetic liposolubility, water
solubility, pharmacokinetics and eventually block characteris-
tics and clinical effects [27].
3.2. Mechanism of action
Neuronal membrane is characterized by a resting potential
generated by electric potential difference (60–90 mV) between
the internal and external membrane [28]. The resting mem-
brane is impermeable to Na+ and there is a concentration gra-
dient between intracellular and extracellular environment
(14 mmol/L and 142 mmol/L) [29]. The depolarizing process
is carried out by electrical charge transfer from outside to
inside of the cell membrane until the reversal of the potential
at which time the Na+ channels are closed [30]. In the process
of repolarization K+ ions move out of the cell to restore the
resting membrane potential [21]. Local anesthetics act after dif-
fusion through the nerve sheath and axonal membrane, con-
version to ionized form, binding of the ionized molecule to
the Na+ channel, blocking the ﬂow of Na+ ions inside the cell,
therefore blocking the neuronal membrane depolarization and
preventing the spread of the electrical impulse throughout the
nerve [31,32]. The main characteristic of the anesthetic agents
is the ability to exist in solution, in both unionized and ionized
forms [33]. The neutral form is less water soluble, but highly
liposoluble which favors crossing the lipidic cell membranes
[34–37].
The ionized form is less liposoluble but strong watersoluble,
which allows binding to speciﬁc receptors on the Na+ channel
and determining closing the channels which stops the Na+
ﬂow and prevents nerve ﬁber depolarization [23,26–28].
3.3. Toxicity of local anesthetics
Systemic toxicity is caused by high concentrations of local
anesthetics. They occur accidentally by injection directly into
the systemic circulation or by overdose [38]. Most sensitive
to the toxic action of local anesthetic agents are central ner-
vous system [39] and cardiovascular system [40,41]. Therefore
92 A.F. Rogobete et al.the symptoms can include isolated muscle contractures, inco-
herent speech, generalized convulsions, loss of consciousness
[42], coma and respiratory depression [43,44].
Cardiovascular changes include tachycardia, slight increase
in arterial tension, followed by PR and QRS prolongation
[27,41]. AV block or various arrhythmias, decreased cardiac
output and accentuated hypotension and ultimately asystole
or ventricular ﬁbrillation [34]. Studies have shown that bupiv-
acaine has a higher afﬁnity for cardiac tissue than lidocaine,
thus cardiovascular collapse occurs faster. Cai et al. [1] have
shown in their study that bupivacaine, tetracaine and etido-
caine have a higher tendency to impair the cardiovascular sys-
tem or depress the central nervous system compared with
lidocaine, mepivacaine and prilocaine [1]. The main obstacle
in using bupivacaine is pronounced systemic toxicity [45,46].Figure 6 Cumulative release of bupivacaine form Exparel and
release of unencapsulated 1.31% w/v and 0.5% w/v bupivacaine
HCl [57].
Figure 7 Sciatic nerve samples harvested from rats 4 day after inje
bupivacaine HCl 1.31% w/v (C) or uninjected sciatic nerve (D) [57].The toxic concentrations initially cause marked sympa-
thetic stimulation, but later myocardial contractility depres-
sion and ventricular arrhythmias carrying the risk of
nonresuscitable cardiac arrest [47]. ECG analysis reveals in
early stages PR prolongation and QRS widening followed by
the appearance of malign arrhythmias [31]. Due to its
increased liposolubility and protein binding (heart muscle
binding is rapid, but elimination is slow), bupivacaine-induced
cardiac arrest is impossible in clinical practice. Pregnant
women [48] are susceptible to cardiotoxicity due to the fact
that cardiac depression is increased by progesterone [49–51].
In order to limit the toxic consequences of bupivacaine and
provide a favorable effect in clinical practice, alternatives have
been developed for controlled release of the active substance in
order to support the motor and sensory local block for a
longer period of time, thus enhancing patient safety.
For this purpose, a number of biomaterials are being stud-
ied: lipospheres, microspheres [52], cyclodextrin matrices,
lipid–protein–sugar nanoparticles, microcrystals, implantable
pellets, implantable membranes and, not least liposomal
bupivacaine [53–57].
4. Liposomal bupivacaine
Liposomal bupivacaine has recently been introduced in clinical
practice [56,57] and is tested in many clinical studies on healthy
volunteers in order to obtain long-lasting pain relief in a single
dose administration (DepoFoam bupivacaine, Exparel) [53].
Liposomal bupivacaine consists of liposomal spheres with
diameter between 31.2 lm± 17.8 [53]. In vitro studies regard-
ing controlled release system compared the Exparel complex
with bupivacaine hydrochloride 0.5% (w/v) and 1.31%ction with either Exparel (A), bupivacaine HCl 0.5% w/v (B),
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kinetics proﬁle was identical in the case of hydrochloride from
free bupivacaine with a maximum time release of 48 h, while
regarding the Exparel complex [53,57], the active substance
has been fully released in about 800 h (Fig. 6).
McAlvin et al. [57] studied the effect of liposomal bupiva-
caine on the sciatic nerve in experimental models, and obtained
sensory block for 240 min for the Exparel complex and
120 min for bupivacaine hydrochloride 0.5% (w/w) [57]. After
histological evaluation, they found that both Exparel complex
and bupivacaine hydrochloride produce tissue reaction, the
liposomal complex being less aggressive. The degree of myco-
toxicity was similar in both pharmaceutical preparations,
which was examined 2 weeks after administration. Also, the
perineural tissue appears normal, without emphasizing signiﬁ-
cant changes in axonal density and myelin structure [57]
(Fig. 7).
Lonner et al. [58] studied the role of liposomal bupivacaine
in pain management after total joint arthroplasty, and
observed that liposomal bupivacaine pharmacokinetics andFigure 8 Plasma bupivacaine concentration after administration of D
total knee arthroplasty [62].
Figure 9 Mean blinded care provider’s satisfaction with analgesia
10 = completely satisﬁed patients analgesia) [62].pharmacodynamics are supporting a minimum concentration
necessary to maintain the therapeutical effect for 72 h without
overconcentrating the active substance in the body [58]. Thus,
liposomal bupivacaine has less cardiac toxic effects, without
signiﬁcant differences between Exparel and placebo: palpa-
tions and extrasystoles (62%) [58], tachycardia (3.9%) [58],
bradycardia (1.6%) [58], hypertension and hypotension
(62%) [58].
Richard et al. [59] showed no signiﬁcant hematological, bio-
chemical and biological side effects of Exparel complex in lab-
oratory animals. Histological analysis 15 days after
administrating Exparel formulation showed evidence of
granulomatous inﬂammation that was resolved without signif-
icant tissue damage. The optimum plasma concentration was
maintained for about 96 h [59]. Liposomal bupivacaine used
in postoperative patients reduces the need for opioids, the hos-
pitalization period and costs by up to 50%, as shown by
Cohen [60] and collaborators in clinical trials involving
sigmoidectomy, cecectomy, hemicolectomy (right or left) in
adult patients [60].epoFoam bupivacaine or bupivacaine HCl to patients undergoing
(rating scale: 0 = completely unsatisﬁed patients analgesia and
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with digital ischemia (ﬁngers 4 and 5) at the right hand. Axil-
lary block was obtained by injecting 3 mL Exparel 1.3% [61].
They found that the results are superior to the subclavicular
block due to a better pain control [61]. After surgery, photopl-
ethysmography showed a normal ulnar artery and disappear-
ance of ﬁnger cyanosis, which was due to the vasodilation
effect created by liposomal bupivacaine [61–64].
Bramlett et al. [62] in a study on analgesic effect of liposo-
mal bupivacaine in patients after total knee arthroplasty,
describe replacing classical continuous femoral blocks [63] with
liposomal bupivacaine Exparel, leading to increased patient
comfort. They also note that for a proper analgesia up to
96 h 532 mg of Bupivacaine DepoFoam 1.3% in just one
administration (Exparel) is necessary [62] (Figs. 8 and 9).5. Conclusions
The use of liposomal bupivacaine in order to obtain motor and
sensory block represents a breakthrough in medical practice.
Long-term analgesia in postoperative patients achieved by
liposomal bupivacaine controlled release systems represents a
great advantage for the safety and patient comfort. Therapeu-
tical action of liposomal bupivacaine sustained up to 96 h after
one administration without toxic concentration, well tolerated,
without side effects and exhibited a predictable kinetic proﬁle.6. Conﬂict of interest
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